Severe birth defects are not included in FDA mandated REMS.

Severe birth defects are not included in FDA mandated REMS.

• A. True
• B. False
• C. Only for certain products
• D. Not applicable

Answer: (B)

REM S are risk management plans the FDA requires for drugs with serious safety concerns to reduce ongoing risk. When a medication is teratogenic or has a high potential to cause birth defects, REMS typically includes measures to prevent fetal exposure, such as mandatory contraception, pregnancy testing, and restricted access. This is why severe birth defects are part of REMS for many products, not excluded. Examples like isotretinoin with the iPLEDGE program and thalidomide’s REMS illustrate how pregnancy prevention and monitoring are integral to these plans. So the statement isn’t correct—birth defects are indeed a key safety concern addressed by FDA-mandated REMS.

REM S are risk management plans the FDA requires for drugs with serious safety concerns to reduce ongoing risk. When a medication is teratogenic or has a high potential to cause birth defects, REMS typically includes measures to prevent fetal exposure, such as mandatory contraception, pregnancy testing, and restricted access. This is why severe birth defects are part of REMS for many products, not excluded. Examples like isotretinoin with the iPLEDGE program and thalidomide’s REMS illustrate how pregnancy prevention and monitoring are integral to these plans. So the statement isn’t correct—birth defects are indeed a key safety concern addressed by FDA-mandated REMS.